In a complaint filed on Monday night in Manhattan federal court, a Detroit-based pension fund said Amgen artificially inflated its stock price by concealing the dispute over its international tax strategy between July 2020 and April 2022.
https://www.pharmalive.com/wp-content/uploads/2020/10/Osteoporosis-drug-helps-Amgen-third-quarter-profit-beat-estimates-Reuters-10-28-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-03-14 09:44:002023-03-14 09:55:01Amgen is sued for concealing $10.7 billion tax bill from investors
